How to Conduct Post-Market Surveillance for Medical Device Registration in Vietnam?

Answer: To conduct post-market surveillance for medical device registration in Vietnam, companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation basis. They should then assess technical files, quality management system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines due to unclear classification, documentation, or authorization arrangements.

Published: 2026-07-10 17:49 | Updated: 2026-07-10 17:49

Based on AIMEILI's regulatory practice question bank, medical device international registration knowledge base, and public regulatory information; specific projects should be subject to the latest requirements of the target country's regulatory authority and product documentation basis.

Key Summary

Regarding 'how to conduct post-market surveillance for medical device registration in Vietnam,' companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation basis. They should then assess technical files, quality management system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines due to unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first conduct product classification and documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Vietnam registration typically affects technical files, authorized representative, importer coordination, label language, quality system certification, and subsequent change maintenance. If the project is advanced only based on 'what documents to submit,' it is easy to encounter corrections or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies incorporate this issue into a unified plan for GHWP member states and multi-country market access strategies, using a reusable core technical file to support localization in different markets, rather than redoing documents from scratch for each country.

Applicable Scenarios and Core Issues

Companies searching for 'how to conduct post-market surveillance for medical device registration in Vietnam' typically want to solve not conceptual explanations, but to determine whether existing documentation can support Vietnam submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect market launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for only one country is not enough. A more valuable approach is to first create reusable versions of core technical files, quality system certification, performance verification, clinical evidence, and labels/instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, usage scenario, method of contact with the human body, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD attributes. Then they can determine the risk classification and submission pathway. Once the pathway is incorrectly determined, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For Vietnam projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in commercial contracts, it can easily affect market control in the later stages.

Documents and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system certification, technical files, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer's declarations, and post-market surveillance documents.

The key to document quality is not quantity, but consistency. Claims in instructions for use, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and information in registration application forms must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, rather than whether the company uploaded many documents.

Common Mistakes

The most common problem for companies is treating registration projects as simple document submissions without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating and submitting domestic NMPA documents without rearranging evidence according to the Vietnam pathway.
• Too many model specifications, but insufficient coverage in test reports, clinical evidence, or labels.
• Selecting a local agent only based on sales cooperation, without clarifying regulatory responsibilities, certificate control rights, and post-market maintenance responsibilities.
• Inconsistencies between labels, instructions for use, promotional materials, and registration document claims, leading to corrections or post-market compliance risks.
• Failure to plan for multi-country document reuse in advance, resulting in repeated preparation for each country and increased costs and timelines.

Enterprise Preparation Checklist

Before starting the project, companies are advised to use an internal checklist to confirm the documentation basis, avoiding the discovery of key evidence gaps only after entering the submission process.

• Organize the target product list, model/specification matrix, and intended use description.
• Verify whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control rights, and exit mechanisms of the local agent or authorized representative.
• Establish a gap assessment table for the target country, specifying content that requires additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view Vietnam registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, and then converting according to national requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, regulatory responsibility boundaries of local partners. If these three are unclear, even if the documents appear numerous, the project may still experience repeated issues during corrections, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be directly used for Vietnam registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear responsibilities can affect certificate control rights and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage product lists, model specifications, registration pathways, document owners, translation status, testing status, local agent communication records, and expected submission times in a single table. This allows for timely identification of documentation gaps and helps management determine whether the project will affect market launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labels and instructions for use, clinical evaluation, risk management, performance verification, and quality system certificates must maintain version consistency.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control rights.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory authorities typically check whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical files are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model specifications, or instructions for use version are inconsistent with test reports, even if the company has prepared many documents, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, matching product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labels and instructions for use version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of corrections, especially for projects submitted simultaneously to multiple GHWP member states or multiple product series.

Localization Conversion and Agent Responsibilities

Vietnam registration projects typically involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents, or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control rights and subsequent market stability.

Labels, instructions for use, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest a lot of effort in obtaining the certificate but neglect post-market maintenance. Subsequently, once there is a manufacturing address change, model expansion, instructions for use update, or agent replacement, it is easy for the certificate and market sales to become disconnected.

AIMEILI recommends that companies incorporate this issue into annual international registration plan management: first clarify target market priorities, then establish a reusable document package and national gap list, and finally arrange submission, correction, post-market maintenance, and renewal milestones. The value of doing this is not only to improve registration efficiency in a single country, but more importantly to enable companies to develop replicable overseas compliance capabilities and reduce the cost of starting from scratch every time they enter a new market.

Continued Reading

• Previous: Common Reasons for Supplementary Corrections in Vietnam Medical Device Registration Documents
• Next: When Are Registration Changes Required for Medical Device Registration in Vietnam?
• Recommended Reading: How to Prepare Registration Documents for Medical Device Registration in Malaysia?
• Recommended Reading: How to Determine Product Classification for Medical Device Registration in Malaysia?
• Recommended Reading: How to Organize Technical Files for Medical Device Registration in Malaysia?
• Recommended Reading: How to Localize Labels and Instructions for Medical Device Registration in Malaysia?
• Recommended Reading: How to Prepare Clinical Evaluation Documents for Medical Device Registration in Malaysia?
• Recommended Reading: Can Test Reports Be Reused for Medical Device Registration in Malaysia?
• Return to FAQ Center
• News & Information
• Contact AIMEILI

Content Review and Scope of Application

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as auxiliary judgment.

Scope of Application: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.